{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:55:06Z","timestamp":1790398506940,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0257-7","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:44:57Z","timestamp":1540471497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature"],"prefix":"10.1186","volume":"19","author":[{"given":"Hans Benno","family":"Leicht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Weinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Viebahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-4044","authenticated-orcid":false,"given":"Monika","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"257_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21307\/immunohematology-2019-098","volume":"30","author":"PA Arndt","year":"2014","unstructured":"Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology. 2014;30:44\u201354.","journal-title":"Immunohematology"},{"key":"257_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1537-2995.2011.03321.x","volume":"52","author":"PA Arndt","year":"2012","unstructured":"Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2012;52:602\u201312.","journal-title":"Transfusion"},{"key":"257_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","volume":"24","author":"G Garratty","year":"2010","unstructured":"Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143\u201350.","journal-title":"Blood Rev"},{"key":"257_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14740338.2012.678832","volume":"11","author":"G Garratty","year":"2012","unstructured":"Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012;11:635\u201342.","journal-title":"Expert Opin Drug Saf"},{"key":"257_CR5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21307\/immunohematology-2019-100","volume":"30","author":"G Garratty","year":"2014","unstructured":"Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30:66\u201379.","journal-title":"Immunohematology"},{"key":"257_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000440673","volume":"42","author":"B Mayer","year":"2015","unstructured":"Mayer B, Bartolmas T, Yurek S, Salama A. Variability of findings in drug-induced immune Haemolytic Anaemia: experience over 20 years in a single Centre. Transfus Med Hemother. 2015;42:333\u20139.","journal-title":"Transfus Med Hemother"},{"key":"257_CR7","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1060028014548310","volume":"48","author":"G Neuman","year":"2014","unstructured":"Neuman G, Boodhan S, Wurman I, Koren G, Bitnun A, Kirby-Allen M, Ito S. Ceftriaxone-induced immune hemolytic anemia. Ann Pharmacother. 2014;48:1594\u2013604.","journal-title":"Ann Pharmacother"},{"key":"257_CR8","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/MPH.0000000000000181","volume":"37","author":"MS Northrop","year":"2015","unstructured":"Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol. 2015;37:e63\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"257_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17843286.2016.1180829","volume":"72","author":"M De Wilde","year":"2017","unstructured":"De Wilde M, Speeckaert M, Callens R, Van Biesen W. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of \u2018chronic Lyme disease. Acta Clin Belg. 2017;72:133\u20137.","journal-title":"Acta Clin Belg"},{"key":"257_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"257_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","volume":"2009","author":"G. Garratty","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematol Am Soc Hematol Educ Program. 2009;2009:73\u20139","journal-title":"Hematology"},{"key":"257_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bcpt.12165","volume":"114","author":"G Oswald","year":"2014","unstructured":"Oswald G, Alzoubi K, Abed M, Lang F. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol. 2014;114:311\u20137.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"257_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21307\/immunohematology-2019-102","volume":"30","author":"RM Leger","year":"2014","unstructured":"Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30:85\u201394.","journal-title":"Immunohematology"},{"key":"257_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/pai.12140","volume":"25","author":"W Liu","year":"2014","unstructured":"Liu W, Yu D. Adverse drug reactions during ceftriaxone treatment can cause severe hemolysis. Pediatr Allergy Immunol. 2014;25:101\u20132.","journal-title":"Pediatr Allergy Immunol"},{"key":"257_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/pbc.26101","volume":"63","author":"LH Pecker","year":"2016","unstructured":"Pecker LH, Timsar A, Pary PP, Denomme GA, Criss VR, Luban NL, Hwang EI, Wong EC. Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma. Pediatr Blood Cancer. 2016;63:1852\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"257_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1537-2995.2008.02028.x","volume":"49","author":"P Arndt","year":"2009","unstructured":"Arndt P, Garratty G, Isaak E, Bolger M, Lu Q. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and\/or drug-induced nonimmunologic protein adsorption. Transfusion. 2009;49:711\u20138.","journal-title":"Transfusion"},{"key":"257_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/INF.0b013e3181629a55","volume":"27","author":"K Quillen","year":"2008","unstructured":"Quillen K, Lane C, Hu E, Pelton S, Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J. 2008;27:357\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"257_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/trf.14536","volume":"58","author":"NL Van Buren","year":"2018","unstructured":"Van Buren NL, Gorlin JB, Reed RC, Gottschall JL, Nelson SC. Ceftriaxone-induced drug reaction mimicking acute splenic sequestration crisis in a child with hemoglobin SC disease. Transfusion. 2018;58:879\u201383.","journal-title":"Transfusion"},{"key":"257_CR19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21307\/immunohematology-2019-101","volume":"30","author":"A Salama","year":"2014","unstructured":"Salama A, Mayer B. Diagnostic pitfalls of drug-induced immune hemolytic anemia. Immunohematology. 2014;30:80\u20134.","journal-title":"Immunohematology"},{"key":"257_CR20","doi-asserted-by":"publisher","first-page":"e2064","DOI":"10.1038\/cddis.2015.392","volume":"7","author":"JW Deuel","year":"2016","unstructured":"Deuel JW, Schaer CA, Boretti FS, Opitz L, Garcia-Rubio I, Baek JH, Spahn DR, Buehler PW, Schaer DJ. Hemoglobinuria-related acute kidney injury is driven by intrarenal oxidative reactions triggering a heme toxicity response. Cell Death Dis. 2016;7:e2064.","journal-title":"Cell Death Dis"},{"key":"257_CR21","first-page":"500","volume":"5","author":"JM Rifkind","year":"2014","unstructured":"Rifkind JM, Mohanty JG, Nagababu E. The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Front Physiol. 2014;5:500.","journal-title":"Front Physiol"},{"key":"257_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1445-5994.2008.01656.x","volume":"38","author":"D Dinesh","year":"2008","unstructured":"Dinesh D, Dugan N, Carter J. Intravascular haemolysis in a patient on ceftriaxone with demonstration of anticeftriaxone antibodies. Intern Med J. 2008;38:438\u201341.","journal-title":"Intern Med J"},{"key":"257_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s001340000598","volume":"26","author":"A Seltsam","year":"2000","unstructured":"Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 2000;26:1390\u20134.","journal-title":"Intensive Care Med"},{"key":"257_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.24953\/turkjped.2016.02.016","volume":"58","author":"A Vehapoglu","year":"2016","unstructured":"Vehapoglu A, Goknar N, Tuna R, Cakir FB. Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin. Turk J Pediatr. 2016;58:216\u20139.","journal-title":"Turk J Pediatr"},{"key":"257_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pbc.20839","volume":"50","author":"G Kapur","year":"2008","unstructured":"Kapur G, Valentini RP, Mattoo TK, Warrier I, Imam AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer. 2008;50:139\u201342.","journal-title":"Pediatr Blood Cancer"},{"key":"257_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.12659\/AJCR.903507","volume":"18","author":"J Tasch","year":"2017","unstructured":"Tasch J, Gonzalez-Zayaz P. Ceftriaxone-induced hemolytic Anemia in a Jehovah's witness. Am J Case Rep. 2017;18:431\u20135.","journal-title":"Am J Case Rep"},{"key":"257_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1309\/AJCPBVLJZH6W6RQM","volume":"136","author":"A Pierce","year":"2011","unstructured":"Pierce A, Nester T, Education Committee of the Academy of Clinical Laboratory P, Scientists. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011;136:7\u201312.","journal-title":"Am J Clin Pathol"},{"key":"257_CR28","first-page":"9181698","volume":"2016","author":"K Ma","year":"2016","unstructured":"Ma K, Caplan S. Refractory IgG warm autoimmune hemolytic Anemia treated with Eculizumab: a novel application of Anticomplement therapy. Case Rep Hematol. 2016;2016:9181698.","journal-title":"Case Rep Hematol"},{"key":"257_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.hoc.2015.01.009","volume":"29","author":"AM Risitano","year":"2015","unstructured":"Risitano AM. Current and future pharmacologic complement inhibitors. Hematol Oncol Clin North Am. 2015;29:561\u201382.","journal-title":"Hematol Oncol Clin North Am"},{"key":"257_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00109-018-1678-x","volume":"96","author":"Y Li","year":"2018","unstructured":"Li Y, Clow F, Fraser JD, Lin F. Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. J Mol Med (Berl). 2018;96:965\u201374.","journal-title":"J Mol Med (Berl)"},{"key":"257_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/CIRCULATIONAHA.115.019955","volume":"134","author":"JA Graw","year":"2016","unstructured":"Graw JA, Mayeur C, Rosales I, Liu Y, Sabbisetti VS, Riley FE, Rechester O, Malhotra R, Warren HS, Colvin RB, et al. Haptoglobin or Hemopexin therapy prevents acute adverse effects of resuscitation after prolonged storage of red cells. Circulation. 2016;134:945\u201360.","journal-title":"Circulation"},{"key":"257_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","volume":"121","author":"DJ Schaer","year":"2013","unstructured":"Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121:1276\u201384.","journal-title":"Blood"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0257-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T17:15:48Z","timestamp":1662311748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0257-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0257-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent from the patient for this case report was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"67"}}